New combination: FDA approved the combination tablet of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (Truvada, Gilead Sciences) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 in adults at high-risk in combination with safer sex practices.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Truvada (Emtricitabine/tenofovir disoproxil fumarate tablets)

Newsletter